Compare LRMR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRMR | RCKT |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.5M | 277.7M |
| IPO Year | 2014 | 2014 |
| Metric | LRMR | RCKT |
|---|---|---|
| Price | $3.03 | $2.32 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | ★ $14.40 | $8.58 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,102.46 |
| P/E Ratio | ★ N/A | $3.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $2.17 |
| 52 Week High | $6.42 | $5.45 |
| Indicator | LRMR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 41.72 |
| Support Level | $2.89 | $2.23 |
| Resistance Level | $4.19 | $2.73 |
| Average True Range (ATR) | 0.25 | 0.19 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 95.93 | 24.84 |
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.